Mechanisms of the antitumoral effect of lipid A

BioEssays

Volumn 24, Issue 3, 2002, Pages 284-289

  Reisser, Danièle ^a   Pance, Alena ^a   Jeannin, Jean François ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS);

ANTINEOPLASTIC AGENT; LIPID A;

ANIMAL; DISEASE MODEL; EXPERIMENTAL NEOPLASM; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LIPID A; NEOPLASMS, EXPERIMENTAL;

EID: 0036006172     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10053     Document Type: Article

References (74)

1. The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and bacillus prodigiosus
2. Chemical treatment of tumors. V Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate
3. Similarities of the anti-tumour actions of endotoxin, lipid A, and double-stranded RNA
4. Preparation and antitumor activity of nontoxic lipid A
5. Adjuvant and antitumour activities of synthetic lipid A analogues
6. Biological activities and antitumor effects of synthetic lipid A analog linked N-acetylated serine
7. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat
8. Antitumor mechanism of intradermal administration of lipopolysaccharide
9. Cure of colon cancer metastasis in rats with a new lipid A OM-174. Apoptosis of tumor cells and immunization of rats
10. Role of tumor necrosis factor in the tumor-necrotizing activity of agents with diverging cytotoxicity
11. Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models
12. Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects
13. DT-5461a, a synthetic lipid A analog, causes selective blood flow reduction in tumor tissue
14. Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog
15. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461
16. Restoration of immune reponse in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative
17. Induction of tumor necrosis factor in a murine tumor by systemic administration of a novel synthetic lipid A analogue, ONO-4007
18. Intratumoral necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog
19. Involvement of T lymphocytes in curative effect of a new immunomodulator OM-163 on rat colon cancer metastases
20. ONO-4007, a new lipid A derivative, induces differentiation of rat myelomonocytic leukemia cells in vitro and in vivo
21. Immunomodulator OM-163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-β1 in vivo
22. A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor-necrosis factor-α in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells
23. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-α
24. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells
25. Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model VX2 carcinoma in rabbits
26. Mechanistic analysis of high antitumor effect of intradermal administration of lipopolysaccharide from Pantoea agglomerans
27. Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats
28. Early signaling events by endotoxin in PC12 cells: Involvement of tyrosine kinase, constitutive nitric oxide synthase, cGMP-dependent protein kinase, and Ca2+ channels
29. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein
30. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: Mutations in Tlr4 gene
31. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4
32. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14-dependent manner
33. The human toll signaling pathway: Divergence of nulear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)
34. Protein kinase C ζ plays a central role in activation of the p42/44 mitogen-activated protein kinase by endotoxin in alveolar macrophages
35. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: Glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK
36. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
37. Lipopolysaccharide internalization activates endotoxin-dependent signal transduction in cardiomyocytes
38. An endotoxin-induced serum factor that causes necrosis of tumors
39. TRADD-TRAF2 and TRADD-FADD interactions define two receptor1 signal transduction pathways
40. Correlation between the capacity to activate macrophages in vitro and the antitumor activity of lipopolysaccharides from different bacterial species
41. Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages
42. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ, receptors
43. IFN-α suppresses activation of nuclear transcription factors NF-κB and activator protein 1 and potentiates TNF-induced apoptosis
44. Interleukin-1
45. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: Involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions
46. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats
47. Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo
48. Tolerance, danger, and the extended family
49. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo
50. The P13 kinase, p38 SAP kinase, and NF-γB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells
51. The immunological basis of endotoxin-induced tumor regression: Requirement for T cell-mediated immunity
52. Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells
53. Active specific immunotherapy of a murine adenocarcinoma using a synthetic tumor-associated glycoconjugate
54. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GLA-60
55. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer
56. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients
57. Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients
58. Endotoxin tolerance: Regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients
59. Intradermal administration of lipopolysaccharide in treatment of human cancer
60. Phase-I study of intravenous modified lipid A
61. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MLR 953 in cancer patients
62. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide
63. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant
64. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action
65. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (Theraccine) in the treatment of disseminated malignant melanoma
66. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma
67. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant
68. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis
69. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
70. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
71. Pre-immunotherapy serum CA27-29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
72. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
73. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and Theratope STn-KLH cancer vaccine
74. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors